Serum Level of GDNF is Associated with Adherence to Methadone Maintenance Treatment

Background: Preclinical studies have shown that neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), are involved in the modulation of biochemical and behavioral adaptations to substance use. Methods: We studied the impact o...

Full description

Saved in:
Bibliographic Details
Published inArchives of neuroscience Vol. 10; no. 3
Main Authors Afghani, Aida, Razaghi, Emran M, Rastgoo Sisakht, Reza, Farhoudian, Ali, Vousooghi, Nasim
Format Journal Article
LanguageEnglish
Published 26.09.2023
Online AccessGet full text

Cover

More Information
Summary:Background: Preclinical studies have shown that neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), are involved in the modulation of biochemical and behavioral adaptations to substance use. Methods: We studied the impact of GDNF and BDNF serum levels on adherence to methadone maintenance treatment (MMT) through cross-sectional research. Participants were clients on MMT (43 males), subjects in remission from opioid use disorder (12 males), and healthy controls (20 males). Adherence and non-adherence to treatment were assessed by the detection of illicit opioids in random urinalysis. Results: Using t-tests for independent groups and analysis of variance (ANOVA), GDNF serum levels in the adherent patients to MMT were found to be significantly higher than in the non-adherent patients. BDNF serum levels were not different between adherent and non-adherent patients. Conclusions: Our results suggest the involvement of GDNF as a biological factor in adherence to MMT.
ISSN:2322-3944
2322-5769
DOI:10.5812/ans-139049